[ad_1]
Treatment by a board of health of 14 patients who died of bad cancer will be reviewed by an independent expert after the bosses admitted that hundreds of patients had received lower doses of chemotherapy.
The NHS Tayside is in the process of modifying its chemotherapy treatment after a surveillance report revealed that patients were receiving a lower dose of medication than in the rest of Scotland.
Healthcare Improvement Scotland (HIS) found that patients were not informed of the difference in treatment at that time.
The health commission has since written to 304 patients who underwent chemotherapy for bad cancer from 1 December 2016 to this month.
They were offered an appointment with an oncologist.
According to the NHS Tayside, 14 of these patients have died and an independent expert will review the treatment that these women received.
A Health Council spokesperson said, "As part of our response to the HIS report, the NHS Tayside asked an independent expert to review the chemotherapy treatment of bad cancer in 14 deceased patients.
"These patients received chemotherapy for bad cancer during the period from December 1, 2016 to March 31, 2019.
"The results will be shared with families."
Doctors Catherine Calderwood, chief of medical services, and Rose Marie Parr, head of pharmaceuticals, ordered her team to conduct an investigation after concerns were expressed "about differences in treatment compared to drugs". other health councils in Scotland ".
We published a report on the clinical management of bad cancer in the NHS Tayside: https: //t.co/jIjcVpZ0M1 pic.twitter.com/gueFZUYcrC
– Healthcare Improvement Scotland (@online_his) April 1, 2019
The report warned against a "dysfunctional team environment" within the NHS Tayside, with a debate on the topic said "smothered".
Other health professionals on the board "expressed concern" about dosage reduction, the report said.
For patients treated with FEC-T chemotherapy, oncologists from the NHS Grampian and NHS Highland recommended doses of 100 mg / m2 of two of the drugs, epirubicin and docetaxel, while in Tayside, the recommended dose was 75 mg / m2 of epirubine and 80 mg / m2 of docetaxel.
The report noted that the practice in the NHS at Tayside was "also at odds with the rest of the NHS in Scotland".
NHS Tayside's team of bad cancer consultants confirmed that patients were not informed about dosage or dosage variation during the consent process, "says the report.
The doctors had claimed that their practice was "in the best interest of NHS Tayside patients," claiming that when higher doses of drugs had been used in 2014-2015, 51 of the 98 patients needed a reduction. of their dosage.
Professor Peter Stonebridge, Acting Medical Director of the Health Council, apologized for any "distress" caused by the report.
He added: "We received badurance from the expert group that said the risk of negative impact on patients resulting from the change of chemotherapy was very low.
"However, patient safety is still our number one priority and that is why we have taken steps to rapidly change our approach to bad cancer chemotherapy, ensuring that it complies to practice in force in the rest of Scotland. "
[ad_2]
Source link
